September 05, 2010

CLOSE
confirmation text

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us

Inflammatory Bowel Disease Monitor

» Advanced search

Please login to access this article in full.
Click here to register for free now!

Registered users login here:

Email Address:
Password:

If you have forgotten your password click here


1 ratings / 4 average

Management of Postoperative Crohn’s Disease

Joseph Rodemann, MD, and Miguel Regueiro, MD

Crohn’s disease is a chronic, relapsing, inflammatory disorder of unknown etiology that can involve the entire gastrointestinal tract. Crohn’s disease affects approximately 500 000 patients in the US and frequently requires both medical and surgical management [1]. Approximately 80% of Crohn’s disease patients will require surgery in their lifetime [2]. While surgery removes the diseased intestine, it is not curative and recurrence is common. In Crohn’s disease patients who have undergone a resection due to disease, the endoscopic recurrence rate of disease at 1 year is 70–90% [3,4]. A much smaller proportion of patients have clinical recurrence of disease at 1 year – as low as 20–37% [3,4].

Please login or register to continue reading this article

Return to top

Post Page On

Your First Name

Your Surname

Recipient's Email Address *

To automatically send an email containing a link to this page, please enter the recipient's email address and your name (optional).

LATEST ARTICLES

Leading Articles
- Mucosal Healing and Treatment Efficacy in IBD
  
  Gert van Assche, MD, PhD, Séverine Vermeire, MD, PhD, and Paul Rutgeerts, MD
  
  Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
  
  Mucosal healing has long been incorporated into the assessment of treatment efficacy in ulcerative colitis; however, in Crohn’s disease this concept has only recently emerged after the evaluation of biological therapies in clinical trials. Systemic steroids do not induce mucosal healing in Crohn’s disease, but purine analogues and anti-tumor necrosis factor (anti-TNF) agents do have the potential to heal mucosal ulcerations. Evidence for mucosal healing has now been provided for the anti-TNF agents infliximab, adalimumab, and certolizumab.
- Management of Lack and Loss of Response to Anti-Tumor Necrosis Factor Therapy
  
  Anne Christine W Vos, Herma H Fidder, MD, PhD, Gijs R van den Brink, MD, PhD, and Daniel W Hommes, MD, PhD
  
  Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
  
  The introduction of biologics has proven a significant breakthrough in the treatment of Crohn’s disease. At the present time, three anti-tumor necrosis factor (anti-TNF) agents are approved by the US Food and Drug Administration for the treatment of Crohn’s disease: infliximab, adalimumab, and certolizumab. Although anti-TNF therapy has been widely studied in clinical trials and found to be effective in Crohn’s disease, approximately one-third of patients do not respond to induction therapy, and around one-third of initial responders lose their response after several months of treatment. In this review, factors associated with lack of response (primary non-responders) and loss of response (secondary non-responders) are discussed. Identifying factors associated with lack and/or loss of response could be helpful in the selection of patients who are likely to benefit from anti-TNF therapy.
- Management of Postoperative Crohn’s Disease
  
  Joseph Rodemann, MD, and Miguel Regueiro, MD
  
  Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
  
  The majority of patients with Crohn’s disease require surgery at some point. Postoperative Crohn’s disease recurrence is common after intestinal resection. The optimal management strategy for postoperative recurrence of Crohn’s disease is controversial. In the absence of universally adopted guidelines, clinicians and patients must discuss and balance the risks and benefits of postoperative pharmacotherapy. Those at a low risk of disease recurrence may not require treatment. On the other hand, patients with more aggressive disease and a high risk of recurrence may be best treated early in the postoperative period with an immunomodulator or anti-tumor necrosis factor agent. Ideally, postoperative treatment decisions would be made using predictable, reliable, and reproducible clinical prediction criteria that would guide treatment. This article reviews the data on postoperative Crohn’s disease – including definitions of postoperative recurrence, surveillance of postoperative recurrence, risk factors, and medications for prevention of recurrence.
Clinical Reviews
Meeting Reports
- Digestive Disease Week 2009  (DDW 2009): Key Updates in  IBD Clinical Research
  
  Uma Mahadevan, MD, and Fernando Velayos, MD, MPH
  
  Chicago, IL, USA, 30 May–4 June, 2009
  UCSF Center for Colitis and Crohn’s Disease, San Francisco, CA, USA
  
  Digestive Disease Week (DDW) 2009 featured several important presentations about the optimal medical management of patients with IBD. Novel methods of determining disease activity, safety of medications with respect to impact on colorectal cancer and pregnancy, optimizing efficacy and duration of medical therapy, and effects on outcomes other than clinical remission (e.g. mucosal healing and fistula closure) were all discussed and are summarized below.

EPIDEMIOLOGY
(Volume 10 Issue 1 / Clinical Reviews)
Digestive Disease Week 2009: Key Updates in IBD Basic Science
(Volume 10 Issue 1 / Meeting Reports)
Management of the Extraintestinal Manifestations of IBD
(Volume 10 Issue 1 / Leading Articles)
The Role of Immunization in Reducing Infections in Patients with IBD
(Volume 09 Issue 4 / Leading Articles)
Enteral Nutrition in IBD
(Volume 09 Issue 4 / Leading Articles)
Pain Management in IBD
(Volume 10 Issue 1 / Leading Articles)

Digestive Disease Week 2009  (DDW 2009): Key Updates in  IBD Clinical Research
(Volume 10 Issue 2 / Meeting Reports)
Management of Postoperative Crohn’s Disease
(Volume 10 Issue 2 / Leading Articles)

Adherent–Invasive Escherichia coli: Role in Crohn’s Disease Pathogenesis
(Volume 10 Issue 3 / Leading Articles)

© Remedica 2010. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of the copyright owners. While every effort is made by the publishers and editorial board to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to make it clear that the material contained in the publication represents a summary of the independent evaluations and opinions of the authors and contributors. As a consequence, the board, publishers, and any supporting company accept no responsibility for the consequences of any such inaccurate or misleading data or statements. Neither do they endorse the content of the publication or the use of any drug or device in a way that lies outside its current licensed application in any territory. For detailed information on any drugs or devices discussed in this publication, readers are advised to consult the manufacturer’s prescribing information.

Produced and published by Remedica Medical Education and Publishing Limited.

September 05, 2010

CLOSE
confirmation text

Produced and published by Remedica Medical Education and Publishing Limited.

» Contact us